[1]李彩东,王信,张伟.参芪心舒胶囊中黄芪甲苷、芍药苷和丹参酮ⅡA含量的测定*[J].西部中医药,2013,26(10):17-21.
　LI Caidong,WANG Xin,ZHANG Wei.Assaying of Astragaloside Ⅳ, Peoniflorin and TanshinoneⅡA in ShenQi XinShu Capsule[J].Western Journal of Traditional Chinese Medicine,2013,26(10):17-21.
点击复制

参芪心舒胶囊中黄芪甲苷、芍药苷和丹参酮ⅡA含量的测定*
分享到：

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
26
期数:
2013年10期
页码:
17-21
栏目:
出版日期:
2013-10-15

文章信息/Info

Title:
Assaying of Astragaloside Ⅳ, Peoniflorin and TanshinoneⅡA in ShenQi XinShu Capsule
文章编号:
1004-6852(2013)10-0017-05
作者:
李彩东，王信，张伟
兰州市第二人民医院肝病研究所，甘肃 兰州 730046
Author(s):
LI Caidong, WANG Xin, ZHANG Wei
Institute of Hepatopathy in Lanzhou Municipal the Second People's Hospital, Lanzhou 730046, China
关键词:
参芪心舒胶囊; 黄芪甲苷; 芍药苷; 丹参酮ⅡA; 含量测定
Keywords:
ShenQi XinShu Capsule;  Astragaloside Ⅳ;  Peoniflorin;  TanshinoneⅡA;  assaying
分类号:
R285
文献标志码:
A
摘要:
目的：建立参芪心舒胶囊中黄芪甲苷、芍药苷、丹参酮ⅡA的含量测定方法，并对其进行含量测定。方法：运用高效液相色谱法（HPLC），黄芪甲苷采用ELSD法检测，芍药苷、丹参酮ⅡA采用二极管阵列检测器检测。结果：测得参芪心舒胶囊中黄芪甲苷的平均含量为0.0174%，芍药苷的平均含量为0.524%，丹参酮ⅡA的平均含量为0.103%，方法学考察结果满足含量分析要求。结论：建立了参芪心舒胶囊中以上3种成分含量测定方法，该方法精密度高，准确可靠，操作简便，可用于参芪心舒胶囊的含量分析方法，并可为类似制剂或成分的含量测定提供参考。
Abstract:
Objective: To establish the methods for the determination of astragaloside Ⅳ, peoniflorin and tanshinoneⅡA in ShenQi XinShu Capsule and to determine the contents. Method: High performance liquid chromatography was adopted, astragaloside Ⅳ was tested through ELSD method, peoniflorin and tanshinoneⅡA were detected by PDA. Result: Average contents of astragaloside Ⅳ in the capsule reached 0.0174%, the contents of peoniflorin and tanshinoneⅡA accounted for 0.524% and 0.103%, the results of the methodology met the rules of content determination. Conclusion: The methods for the determination of three kinds of ingredients in ShenQi XinShu capsule are established, the methods, accurate, reliable and practicable, could be used for the assaying of ShenQi XinShu capsule to provide reference for other similar assaying.

相似文献/References:

[1]吴忠民,贾 忠△,李喜香,等.黄芪党参颗粒中黄芪甲苷含量的HPLC测定方法[J].西部中医药,2012,25(10):23.
　WU Zhong-min,JIA Zhong,LI Xi-xiang,et al.HPLC Determination of Astragaloside Ⅳ in HuangQi DangShen Granule[J].Western Journal of Traditional Chinese Medicine,2012,25(10):23.
[2]李红,王胜,沈明霞,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织碱性成纤维细胞生长因子(bFGF)表达的影响[J].西部中医药,2015,28(12):21.
[3]李红,沈明霞,谢海彬,等.黄芪甲苷对特发性肺纤维化模型大鼠肺组织CD34表达的影响[J].西部中医药,2015,28(09):6.
[4]刘世军,赵海峰,唐志书△,等.正交设计法优选补阳还五胶囊提取工艺[J].西部中医药,2016,29(04):32.
　LIU Shijun,,et al.Optimization of Extraction Process of BuYang HuanWu Capsules by Orthogonal Design[J].Western Journal of Traditional Chinese Medicine,2016,29(10):32.
[5]刘世军,赵海峰,唐志书,等.薄层扫描法测定补阳还五胶囊黄芪甲苷的含量[J].西部中医药,2016,29(01):30.
　LIU Shijun,ZHAO Haifeng,TANG Zhishu,et al.Determination of Astragaloside Ⅳ in BuYang HuanWu Capsules by TLC[J].Western Journal of Traditional Chinese Medicine,2016,29(10):30.
[6]王晓琳,张平.黄芪饮片与黄芪配方颗粒有效成分含量比较[J].西部中医药,2017,30(02):25.
　WANG Xiaolin,ZHANG Ping.Comparsion of Effective Elements Contents between Slices of Prepared HuangQi and Formula Granules of HuangQi[J].Western Journal of Traditional Chinese Medicine,2017,30(10):25.
[7]武向丽.黄芪甲苷对实验性糖尿病大鼠睾丸组织的保护作用[J].西部中医药,2017,30(11):32.
　WU Xiangli.The Protective Effects of Astragalosides IV on Testicular Tissue of Experimental Diabetic Rats[J].Western Journal of Traditional Chinese Medicine,2017,30(10):32.
[8]刘建平,何建峰.黄芪甲苷对大鼠肺缺血再灌注损伤的保护作用及其机制研究[J].西部中医药,2018,31(02):21.
　LIU Jianping,HE Jianfeng.Study on the Protective Effects of Astragaloside IV to the Rats Suffering from Lung Ischemical Reperfusion Injury and Its Mechanism[J].Western Journal of Traditional Chinese Medicine,2018,31(10):21.
[9]隋晓丽,张红艳,田晓倩,等.肺抑瘤合剂质量标准研究[J].西部中医药,2018,31(09):46.
　SUI Xiaoli,ZHANG Hongyan,TIAN Xiaoqian,et al.Study on Quality Standard of Pulmonary Tumor-inhibiting Mixture[J].Western Journal of Traditional Chinese Medicine,2018,31(10):46.
[10]杨长花,程芬,李慧,等.4个主要黄芪产地黄芪质量比较[J].西部中医药,2019,32(01):27.
　YANG Changhua,CHENG Fen,LI Hui,et al.Quality Comparisons of HuangQi Collected from Four Major Producing Areas[J].Western Journal of Traditional Chinese Medicine,2019,32(10):27.

备注/Memo

备注/Memo:
收稿日期：2013-01-15 *基金项目：2011年兰州市科技局立项项目(编号2011-2-7) 作者简介：李彩东(1969—)，女，博士学位，主任药师。研究方向：药物质量控制。
更新日期/Last Update: 2013-10-15